drugset / Trial / NCT03096457

Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia

NCT03096457

Phase 2/3 Completed 80 enrolled Fundacion Nacional de Dermatologia
RandomizedParallel-groupDouble-blindTreatment

Summary

This protocol will compare topical paromomycin to standard intralesional (IL) antimony (Sb) to placebo for L braziliensis in Bolivia.

Timeline

Start
2017-04-15
Primary completion
2018-03-18
Completion
2018-04-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Paromomycin Small molecule 15 % Topical
Comparator Pentamidine Unknown 120 unknown Intrathecal